Coronary artery diseases in South Asian immigrants: An update on high density lipoprotein role in disease prevention

Journal of Immigrant and Minority Health

Volumn 11, Issue 5, 2009, Pages 415-421

  Dodani, Sunita ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Coronary artery diseases; Dyslipidemias; HDL dysfunction; Risk factors; South Asians

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMMUNITY PROGRAM; CORONARY ARTERY DISEASE; DIETARY INTAKE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; IMMIGRANT; INCIDENCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PHYSICAL ACTIVITY; POPULATION RESEARCH; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; COMPLICATION; DYSLIPIDEMIAS; ETHNOLOGY; FEMALE; INDIA; INFLAMMATION; LIFESTYLE; MALE; PAKISTAN; RISK FACTOR; UNITED STATES;

CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; INDIA; INFLAMMATION; LIFE STYLE; MALE; METABOLIC SYNDROME X; PAKISTAN; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 70349339641     PISSN: 15571912     EISSN: 15571920     Source Type: Journal    
DOI: 10.1007/s10903-008-9183-x     Document Type: Article

References (77)

1. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596-601.
2. Uppaluri CR. Heart disease and its related risk factors in Asian Indians. Ethn Dis. 2002;12(1):45-53.
3. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. J Am Med Assoc. 2007;297(3):286-94. doi: 10.1001/jama.297.3.286.
4. Reddy KS. Cardiovascular diseases in non-Western countries. N Engl J Med. 2004;350:2438-40. doi: 10.1056/NEJMp048024.
5. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol. 2005;39(4):667-79. doi: 10.1016/j.yjmcc.2005.06.006.
6. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of diseases, part 1: general considerations, the epidemiologic transition, risk factors and impact of urbanization. Circulation. 2001;104:2746-53. doi: 10.1161/ hc4601.099487.
7. Enas EA, Garg A, Davidson MA, et al. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48(4):343-53.
8. Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: Thoughts on pathogenesis, prevention, and treatment. Clin Cardiol. 1995;18(3):131-5.
9. Anand SS, Yusuf S, Vuksan V, et al. Difference in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000;356:279-84. doi: 10.1016/S0140-6736(00)02502-2.
10. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, part II: Variations in cardiovascular diseases by specific ethnic groups and geographic and prevention strategies. Circulation. 2001;104:2855-64. doi: 10.1161/hc4701.099488.
11. Murray CJL, Lopez AD. Global health statistics, global burden of disease and injury series. Boston, Mass: Harvard School of Public Health; 1996.
12. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res. 2006;124(3):235-44.
13. Klatsky AL, Tekawa I, Armstrong MA, et al. The risk of hospitalization for ischemic heart disease among Asian Americans in northern California. Am J Public Health. 1994;84(10):1672-75.
14. Bhatnagar D, Anand IS, Durrington PN, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet. 1995;345:405-9.
15. Williams B. Westernized Asians and cardiovascular disease: Nature or nurture. Lancet. 1995;345:401-2. doi: 10.1016/S0140-6736(95)90394-1.
16. Petersen S, Peto V, Rayner M Coronary heart disease statistics, British Heart Foundation, London (2004). Available at http://www.heartstats.org/ datapage.asp?id=1652.
17. Bedi US, Singh S, Syed A, Aryafar H, Arora R. Coronary artery disease in South Asians: An emerging risk group. Cardiol Rev. 2006;14(2):74-80. doi: 10.1097/01.crd.0000182411.88146.72.
18. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-8. doi: 10.1161/01.CIR.0000020650.86137.84.
19. Kuppuswamy VC, Gupta S. Excess coronary heart disease in South Asians in the United Kingdom. BMJ. 2005;330(7502):1223-4. doi: 10.1136/ bmj.330.7502.1223.
20. Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: A UK population-based cross-sectional study. Diabetologia. 2005;48(4):649-56. doi: 10.1007/ s00125-005-1689-3.
21. Forouhi N, McKeigue P. How far can risk factors account for excess coronary mortality in South Asians? Can J Cardiol. 1997;13(Suppl B):47B.
22. Forouhi NG, Sattar N, Tillin T, McKeigue PM, Chaturvedi N. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies. Diabetologia. 2006;49(11):2580-8. doi: 10.1007/ s00125-006-0393-2.
23. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. The Minnesota heart survey investigators. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. N Engl J Med. 1996;334:884-90. doi: 10.1056/NEJM199604043341403.
24. Luepker RV, Arnett DK, Jacobs DR Jr, Duval SJ, Folsom AR, Armstrong C, et al. Trends in blood pressure, hypertension control, and stroke mortality: The Minnesota heart survey. Am J Med. 2006;119(1):42-9. doi: 10.1016/j.amjmed.2005.08.051.
25. Vizza J, Neatrour DM, Felton PM, Ellsworth DL. Improvement in psychosocial functioning during an intensive cardiovascular lifestyle modification program. J Cardiopulm Rehabil Prev. 2007;27(6):376-83.
26. Khunti K, Stone MA, Bankart J, Sinfield P, Pancholi A, Walker S, et al. Primary prevention of type-2 diabetes and heart disease: Action research in secondary schools serving an ethnically diverse UK population. J Public Health (Oxf). 2008;30(1):30-7. doi: 10.1093/pubmed/fdm078.
27. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/texas coronary atherosclerosis prevention study. J Am Med Assoc. 1998;279:1615-22. doi: 10.1001/jama.279.20.1615.
28. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 2002;360:7-22.
29. Enas EA. Coronary artery disease epidemic in Indians: A cause for alarm and call for action. J Indian Med Assoc. 2000;98(11):694-5, 697-702.
30. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: Sub-clinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000;20(3):823-9.
31. Pasternak RC, Abrams J, Greenland P, Smaha LA, Wilson PW, Houston-Miller N. 34th Bethesda conference: Task force #1-identification of coronary heart disease risk: Is there a detection gap? J Am Coll Cardiol. 2003;41(11):1863-74. doi: 10.1016/S0735-1097(03)00358-9.
32. Devine PJ, Carlson DW, Taylor AJ. Clinical value of carotid intima-media thickness testing. J Nucl Cardiol. 2006;13(5):710-8. doi: 10.1016/ j.nuclcard.2006.07.007.
33. Patel SN, Rajaram V, Pandya S, Fiedler BM, Bai CJ, Neems R, et al. Emerging, noninvasive surrogate markers of atherosclerosis. Curr Atheroscler Rep. 2004;6(1):60-8. doi: 10.1007/s11883-004-0117-3.
34. Smith SC, Greenland P, Grundy SM. Prevention conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Executive summary. Circulation. 2000;101:111-6.
35. Rosa EM, Kramer C, Castro I. Association between coronary artery atherosclerosis and the intima-media thickness of the common carotid artery measured on ultrasonography. Arq Bras Cardiol. 2003;80(6):589-92, 285-8.
36. Dodani S, Kaur R, Reed GL, George V, Sharma G, Marion L. The association of carotid intima media thickness with dysfunctional HDL in South Asians. Arch Med Sci. 2008;4(1):40-6.
37. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128(4):262-9.
38. Hulthe J, Wikstrand J, Emanuelsson H, Wiklund O, de Feyter PJ, Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke. 1997;28(6):1189-94.
39. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med. 1999;340(1):14-22. doi: 10.1056/NEJM199901073400103.
40. Geroulakos G, O'Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J. 1994;15(6):781-5.
41. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam study. Circulation. 1997;96(5):1432-7.
42. Granér M, Varpula M, Kahri J, Salonen RM, Nyyssönen K, Nieminen MS, et al. Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol. 2006;97(5):624-9. doi: 10.1016/j.amjcard.2005.09.098.
43. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey BP, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995;92(8):2127-34.
44. Feder G, Crook AM, Magee P, Banerjee S, Timmis AD, Hemingway H. Ethnic differences in invasive management of coronary disease: Prospective cohort study of patients undergoing angiography. BMJ. 2002;324(7336):511-6. doi: 10.1136/bmj.324.7336.511.
45. Farooqi A, Nagra D, Edgar T, Khunti K. Attitudes to lifestyle risk factors for coronary heart disease amongst South Asians in Leicester: A focus group study. Fam Pract. 2000;17(4):293-7. doi: 10.1093/fampra/ 17.4.293.
46. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease four prospective American studies. Circulation. 1989;79:8-15.
47. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin survival study (4S). Lancet. 1994;344:1383-9.
48. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1350-1.
49. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486-97.
50. Kalhan R, Puthawala K, Agarwal S, Amini SB, Kalhan SC. Altered lipid profile, leptin, insulin, and anthropometry in offspring of South Asian immigrants in the United States. Metabolism. 2001;50(10):1197-202. doi: 10.1053/meta.2001.26704.
51. Hoogeveen RC, Gambhir JK, Gambhir DS, Kimball KT, Ghazzaly K, Gaubatz JW, et al. Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res. 2001;42(4):631-8.
52. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. J Am Med Assoc. 2001;286(2):180-7. doi: 10.1001/jama.286.2.180.
53. Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to newcastle heart project data. J Public Health. 2005;27(1):93-100. doi: 10.1093/pubmed/ fdh202.
54. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003;146(2):227-33. doi: 10.1016/S0002-8703(02)94701-0 Review.
55. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. J Am Med Assoc. 1986;256:2835-8. doi: 10.1001/ jama.256.20.2835.
56. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol. 2003;23:712-9.
57. Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, et al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol. 1999;10:329-39. doi: 10.1097/00041433-199908000-00007.
58. Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci United States Am. 1999;96:11358-63. doi: 10.1073/ pnas.96.20.11358.
59. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, et al. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun. 2001;280:818-23. doi: 10.1006/bbrc.2000.4219.
60. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-35.
61. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem. 2002;278:3937-47.
62. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21(5):880.
63. Graham A, Hassall DJ, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:193-204.
64. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res. 2000;41:1481-94.
65. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res. 2000;41:1495-508.
66. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285-8. doi: 10.1097/00041433-200206000-00008.
67. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: Proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2(9):504-11. doi: 10.1038/ ncpendmet0245.
68. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: Is it always atheroprotective? Curr Atheroscler Rep. 2006;8(5):405-11. doi: 10.1007/s11883-006-0038-4.
69. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8. doi: 10.1016/ j.jacc.2005.06.080.
70. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, et al. The double jeopardy of HDL. Ann Med. 2005;37(3):173-8. doi: 10.1080/07853890510007322.
71. Fogelman AM. When good cholesterol goes bad. Nat Med. 2004;10(9):902-3. doi: 10.1038/nm0904-902.
72. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-41.
73. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, et al. Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversal. Curr Opin Lipidol. 2004;15(6):645-9. doi: 10.1097/00041433-200412000-00004.
74. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;42:1308-17.
75. Ansell BJ, Navab N, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by Simvastatin treatment. Circulation. 2003;108:2751-6. doi: 10.1161/01.CIR.0000103624.14436.4B.
76. Dodani S, Dong YB, Zhu H, George V. Can novel Apo A-I polymorphisms be responsible for low HDL in South Asian immigrants? Indian J Hum Genet. 2008;4(1):9-15.
77. Watson KE, Ansell BJ, Watson AD, Fonarow GC. HDL function as a target of lipid-modifying therapy. Rev Cardiovasc Med. 2007;8(1):1-8. doi: 10.1016/ j.carrev.2007.01.003.